connected-grid-1920x500

Our investments

  • William Demant Invest is the majority shareholder in Demant, the leading global hearing healthcare company, Embla Medical, a global leader in non-invasive orthopaedics, as well as Vision RT, a market-leading UK-based medtech company.

  • The investment company also has significant holdings in Vitrolife, CellaVision, Revenio, INVISIO, Jeudan, GN Store Nord and Pleo. The total number of employees around the world within the William Demant Invest family counts more than 35,000. 

Strategic long-term investments

  • investments-logos-frontpage-demant

    55-60%

  • investments-logos-frontpage-embla

    51%

  • investments-logos-frontpage-vision-rt

    93%

  • investments-logos-frontpage-jeudan

    44%

  • investments-logos-frontpagevitrolife

    29%

  • investments-logos-frontpage-cellavision

    20%

  • investments-logos-frontpage-revenio

    21%

  • investments-logos-frontpage-invisio

    18%

Other investments

  • investments-logos-frontpage-pleo

    8%

  • investments-logos-frontpage-gn

    >10%

Below is a short description of strategic long-term investments

2024-demant

Demant A/S

Demant A/S is a leading global company that develops, manufactures and sells hearing instruments, diagnostic instruments and personal communication devices, and the company is behind the commercial successes of such world-renowned brands as Oticon, Bernafon, Sonic, Maico, Interacoustics, Grason-Stadler and EPOS. The Group operates in a global market with companies in more than 30 countries, has around 21,000 employees and generates annual revenues of more than DKK 22 billion. Their products are sold in more than 130 countries. Demant A/S was listed on Nasdaq Copenhagen in 1995.

Learn more

2024-embla

Embla Medical

Embla Medical is a global leader in non-invasive orthopedics, focused on delivering innovative solutions in the prosthetics and bracing and supports market. The company was founded in 1971, is headquartered in Iceland and operates with almost 4,000 employees in 26 countries. In 2024, Embla Medical generated revenue of USD 855 million with an EBITDA margin of 20%. Embla Medical has been listed on the Icelandic Stock Exchange since 1999 and on Nasdaq Copenhagen since 2009.

William Demant Invest started investing in Embla Medical in 2004 and has continually bought up Embla Medical shares. Today, William Demant Invest is the largest shareholder with approx. 51% ownership.


Learn more

2024-vision-rt

Vision RT Ltd.

Vision RT is a UK-based pioneer and leading manufacturer of surface guided radiation therapy (SGRT). The company, which was founded in 2001 by three visionary scientific academics, has pioneered the market of SGRT and is currently the undisputed market leader. The company develops and manufactures camera systems that improve the efficiency, efficacy and patient comfort during radiation therapy cancer treatment. The company has seen very strong growth over the last couple of years, increasing the number of employees to more than 330 in 2024, while still maintaining a very attractive double-digit EBITDA margin.

William Demant Invest acquired approximately 93% of the shares in Vision RT in 2018.

Learn more

2024-vitrolife

Vitrolife AB

Vitrolife was founded in 1994 and was one of the first companies to deal with IVF treatment. Today, Vitrolife is an international healthcare company active within reproductive treatment focusing on medical equipment and consumables for IVF treatment as well as genetic testing services and labs. Vitrolife has around 1,120 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and in 2024, the company’s revenue arrived at SEK 3,609 million with an EBITDA margin of 34%.

William Demant Invest started investing in Vitrolife in 2014, selling its ownership of FertiliTech shares to Vitrolife. Today William Demant Invest owns approx. 29% of the company.

Learn more

2024-cellavision

CellaVision AB

CellaVision is a global leader of digital solutions for medical microscopy in the field of hematology, replacing conventional microscopes by innovative digital and automated solutions. The company develops analysers, software and applications that make it easier, faster and more efficient to carry out blood cell analysis, ranging from among others pre-classification of white-blood cell types to morphological characteristics of red-blood cells.

Today, CellaVision is the only serious provider of a commercially viable solution in the hematology market, with an estimated market penetration rate of around 27%. In 2024, CellaVision’s revenue amounted to SEK 723 million with an EBITDA margin of 30%.

William Demant Invest started investing in CellaVision in 2017 and is today the largest shareholder with approx. 20% ownership.

Learn more

2024-revenio

Revenio Oyj

Revenio operates within ophthalmological devices and software solutions for eye care. The company develops tonometers (intraocular pressure measurement device), fundus imaging devices, perimeters and clinical software solutions under the iCare brand focusing on early-stage detection of globally prevailing eye diseases, including glaucoma, diabetic retinopathy, age-related macular degeneration (AMD) and cataract as well as the monitoring of these diseases during the treatment process.

Revenio is headquartered in Helsinki, Finland, and has more than 200 employees. In 2024, the company’s net sales totaled EUR 104 million with an adjusted EBITDA margin of 29%. Revenio Group is listed on Nasdaq OMX Helsinki.

William Demant Invest started investing in Revenio in 2018 and is today the largest shareholder with approx. 21% ownership.

Learn more

invisio_2023

INVISIO AB

INVISIO is a Danish company operating within advanced communication systems that help professionals in noisy and mission critical environments to work more safely and effectively while protecting their hearing.

The company offers personal communication equipment and hearing protection and an intercom system for defense and security customers. The personal equipment reduces high noise levels and enables disruption-free communication in noisy and mission critical environments. The product portfolio includes headsets, control units and cables. The intercom system enables users of personal equipment to communicate within a group in a vehicle as well as with individuals in the field while being on the move.

INVISIO is listed on Nasdaq OMX Stockholm and headquartered in Copenhagen, Denmark, and has more than 250 employees. In 2024, net sales amounted to SEK 1,807 million with an EBITDA margin of 35%.

William Demant Invest started investing in INVISIO in 2020 and today owns approx. 18% of the company.

Learn more

2024-jeudan

Jeudan A/S

The Jeudan group is Denmark’s largest publicly listed real estate and service company. The group’s activities consist of investment in and operation of commercial and residential properties, mainly in Copenhagen, and a complete offering of advisory services and building within real estate – through Jeudan Servicepartner. In 2024, Jeudan’s revenue arrived at DKK 1,709 million, powered by a portfolio of more than 200 properties with a book value above DKK 35 billion. The company has almost 700 employees.

The group’s strategy aims at continued growth and profitability based on the values “Orderly, Competent and Accessible”. William Demant Invest started investing in Jeudan in 2004 and has continually bought up Jeudan shares. Today, William Demant Invest is, with approx. 44% of the ownership, one of the two largest shareholders.

Learn more